Janssen Biotech, Inc.

Csl Limited

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Northwestern University

New York University

Bioage Labs, Inc.

William Strohl

Zhiqiang An

Gene G Kinney

Andrew Donald Nash

Louis Jerry Fabri

Dennis M Zaller

Manuel Baca

Andrew J Bett

William L Klein

Paul J Shughrue

Mary P Lambert

Xiaoping Liang

Lei Chang

Paul Acton

Robert Breese

Elizabeth Chen Dodson

Omid Vafa

Randall J Brezski

Kirsten L Viola

Bernard Scallon

Victor J Torres

Robert W Hughes

Susan H Tam

Mark Chiu

Brian Whitaker

Anthony S Lynch

Robert Jordan

Peter T Buckley

Kristen Viola

Keri Dorn

Michelle Kinder

John Lee

Richard L Monaghan

Juan C Almagro

Michael Naso

John Wheeler

Maria L Garcia

Gregory J Kaczorowski

Michael A Goetz

Owen B McManus

Mark Tornetta

Gene Kinney

Colleen Kane

Timothy McCabe

Jan S Tkacz

Jill Marie Mooney

Patrick Branigan

Susann Taudte

William Klein

McCarthy Stephen

Stephen McCarthy

Chen Ni Chin

Juan Carlos Almagro

The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.

RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof

BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.

Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof

Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.

Antibody Fc mutants with ablated effector functions

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R&#x3b1;1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R&#x3b1;1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R&#x3b1;1-mediated activities are also disclosed.

High affinity antibody antagonists of interleukin-13 receptor alpha 1

The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of ainfection, including methicillin-resistant

Compositions and methods for phagocyte delivery of anti-staphylococcal agents

Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.

The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with Fc&#x3b3;R receptors except with Fc&#x3b3;RI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.

Active protease-resistant antibody FC mutants

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A&#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid &#x3b2; 1-42.

Anti-ADDL antibodies and uses thereof

Growing community of inventors

Bridgewater, NJ, United States of America

William Strohl